To the editor; Increased Nucleobindin-2 level has been determined as an independent prognostic factor for overall survival of patients [1, 2] . However, pathophysiological significance of Nucleobindin-2 in lung cancers remains unclear. In the present study, we examined Nucleobindin-2 mRNA level in various types of human lung cancer cell lines.
Ten of lung cancer cell lines with EGFR/BRAF/KRAS wildtype (H1299, H1819, HCC95, H838, H1437, H661, HCC15, HCC78, H1648, HCC193) and eleven of lung cancer cell lines with KRAS-mutation [KRAS-G12C (H2122, HCC44, H1792, HCC4017, H358), KRAS-G12V (H441), KRAS-G12D (HCC515), KRAS-G12R (H1264, H157), KRAS-G12A (H2009), KRAS-Q61H (H460)] were used [3]. Nucleobindin-2 mRNA level was analyzed by RT-qPCR as previously rescribed [3] . Primers and probes for Nucleobindin-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were obtained from Ori Gene Technologies (MK203097; Rockville, MD, USA;) and Applied Biosystems (Assay ID: Hs99999905_m1; Tokyo, Japan;), respectively. To normalize the amount of input cDNA, quantitative analysis was performed using the GAPDH as an internal reference. Relative expression values were computed using the comparative cycle threshold (Ct) method. All data in the figure are presented as mean ± standard deviation and were analyzed using one-way ANOVA to compare the means of all the groups. Turkey-Kramer multiple comparisons method was used to determine statistical differences between the means, with p < 0.05 deemed statistically significant using the InStat 2.00 program. Figure 1 , we discovered that lung cancer cell lines associated with KRAS-mutations had significantly
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KRAS-mutations are almost exclusively detected in lung adenocarcinomas [4] . In the case of non small cell lung cancer (NSCLC), KRAS mutations occur predominantly at codon 12 (> 80%) [4] . The most frequent codon variant is KRAS-G12C mutation (39%) [4] . Other common mutations include KRAS-G12V (18-21%) and KRAS-G12D (17-18%) variants [4] . KRAS-mutant lung cancers have generally been associated with poorer overall survival than KRAS wild-type tumors, particularly in the advanced-stage [5] . In the current study, KRAS-G12C was five of eleven, KRAS-G12V was one of eleven, and KRAS-G12D was one of eleven cell lines. Having those sets of KRAS-mutant lung cancer cell lines, we compared Nucleobindin-2 mRNA levels between EGFR/BRAF/KRAS wild-type and KRAS-mutant lung cancer cell lines. Based on our observation, it was speculated that Nucleobindin-2 was downregulated in KRAS-mutant lung cancer cell lines and
